Treatment of Adrenal Insufficiency in Vasculitis

Immediate Management Priorities

For patients with both adrenal insufficiency and active vasculitis, the European League Against Rheumatism recommends treating the vasculitis aggressively with high-dose glucocorticoids combined with either cyclophosphamide or rituximab, while providing stress-dose steroid coverage and careful monitoring for adrenal crisis 1, 2
Administer hydrocortisone 100 mg IV bolus immediately, followed by 100-300 mg/day as continuous infusion or divided doses every 6 hours, as recommended by the European Society of Internal Medicine 3
Provide rapid IV fluid resuscitation with 3-4 L isotonic saline or 5% dextrose in isotonic saline, with initial infusion rate of approximately 1 L/hour, according to the European Society of Internal Medicine 3
The high-dose hydrocortisone (100 mg) saturates 11β-HSD type 2 receptors, providing necessary mineralocorticoid effect during acute crisis, as stated by the European Society of Internal Medicine 3

Initiate remission-induction therapy with glucocorticoids plus either cyclophosphamide or rituximab (Level 1A evidence, Grade A recommendation for GPA/MPA), as recommended by the European League Against Rheumatism 1, 2, 4

Rituximab 375 mg/m² IV weekly for 4 weeks is the standard induction regimen, according to the American College of Rheumatology 6
Rituximab is particularly preferred over cyclophosphamide in relapsing disease, women of childbearing age, or when cyclophosphamide poses fertility risks, as stated by the American College of Rheumatology 6

Maintain initial high-dose prednisolone (1 mg/kg/day, max 60 mg) for one month, as recommended by the European League Against Rheumatism 5
Taper gradually—at 3 months, target dose should be 10-15 mg/day, according to the European League Against Rheumatism 5
Do not use alternate-day therapy, as this increases relapse risk, as stated by the European League Against Rheumatism 5

Rituximab 500 mg IV every 6 months is superior to azathioprine for maintenance therapy, as recommended by the American College of Rheumatology 6
Continue maintenance therapy for at least 18-24 months following induction of sustained remission, according to the European League Against Rheumatism 1, 2, 6

Use structured clinical assessment rather than ANCA testing to guide treatment changes (Level 4 evidence, Grade D recommendation), as recommended by the European League Against Rheumatism 1, 2, 6
For refractory disease after 4 weeks or <50% reduction in disease activity at 6 weeks, switch from cyclophosphamide to rituximab or vice versa, according to the American College of Rheumatology 6

Consider plasma exchange for serum creatinine >3.4 mg/dL (>300 μmol/L), patients requiring dialysis, or rapidly increasing creatinine (Level 1B evidence, Grade B recommendation), as recommended by the European League Against Rheumatism and the International Society of Nephrology 1, 4, 7
Assess cardiovascular risk periodically, as stated by the European League Against Rheumatism 1
Provide bone protection therapy according to local guidelines for all patients on glucocorticoids, as recommended by the European League Against Rheumatism 5